A new study shows that measuring circulating tumor DNA (ctDNA) in the blood just 3 to 4 weeks after starting immunotherapy can reveal which melanoma patients will respond well to treatment and which won't. This early biomarker could transform how doctors manage advanced skin cancer by enabling faster treatment adjustments rather than waiting months for imaging scans. What Is Circulating Tumor DNA and Why Does It Matter? Circulating tumor DNA is genetic material from cancer cells that leaks into the bloodstream. Researchers at the University of Wisconsin Carbone Cancer Center analyzed 117 patients with advanced melanoma (median age 64.5 years, 62.4% men) who received anti-PD-1 immunotherapy, a type of checkpoint inhibitor that helps the immune system recognize and attack cancer cells. The findings were striking. Patients whose ctDNA levels decreased from baseline had more than 30 times the likelihood of achieving disease control compared to those with increasing ctDNA levels. They also had 20 times greater odds of having an objective response, meaning their tumors shrank measurably. "Those were striking differences at a very early time point," said Dr. Vincent T. Ma, assistant professor in the division of hematology, medical oncology and palliative care at the University of Wisconsin Carbone Cancer Center. The survival improvements were equally impressive: patients with decreasing ctDNA showed more than 80% improvement in progression-free survival (how long before cancer returns) and 70% improvement in overall survival compared to those with rising ctDNA levels. How Do Current Melanoma Treatments Work? Multiple immune checkpoint inhibitors have been approved for advanced melanoma, including anti-CTLA-4, anti-PD-1, and anti-LAG-3 targeted therapies. These drugs work by removing the "brakes" that cancer cells use to hide from the immune system, allowing T cells to attack tumors more effectively. However, the challenge is significant: roughly 50% of melanoma patients don't respond adequately to these immunotherapies. Additionally, doctors typically must wait 2 to 4 months before obtaining imaging scans to assess whether treatment is working, and even then, interpreting results can be difficult because inflammatory changes in tumors can mimic cancer progression. What Do the Study Results Actually Show? The research revealed dramatic differences between patients based on their early ctDNA response. Among patients with increased ctDNA levels, the median progression-free survival was just 2.3 months, with only 23.1% surviving without cancer progression at 12 months. Their median overall survival was 14.1 months, with 43.5% alive at 12 months. In stark contrast, patients with decreased ctDNA had a 12-month progression-free survival rate of 67.6% and a 12-month overall survival rate of 77.5%. Even more remarkably, among patients whose ctDNA completely cleared from their blood, the 12-month progression-free survival jumped to 78.6% and overall survival reached 92.3%. How Could This Change Treatment Decisions? The most practical implication is personalized medicine during active treatment. Rather than continuing a single therapy for months while waiting for imaging results, doctors could use early ctDNA measurements to make faster decisions. Patients with rising ctDNA levels could be considered for switching to BRAF/MEK-targeted therapy (a different class of drugs that targets specific genetic mutations) or proceeding with tumor-infiltrating lymphocyte therapy, a more intensive immunotherapy approach. "No longer are we thinking about just throwing the whole kitchen sink at patients," Dr. Ma explained. "We're tailoring the treatment approach based on how well patients are doing early on, and thinking about this idea of personalized medicine during the actual course of therapy". Steps to Implementing ctDNA Testing in Melanoma Care - Baseline Testing: Obtain a ctDNA measurement before starting immunotherapy to establish a patient's starting point and identify those with higher initial tumor burden. - Early Reassessment: Measure ctDNA again at 3 to 4 weeks after beginning treatment to determine whether levels are decreasing, stable, or increasing. - Treatment Adjustment: Use the early ctDNA results to inform decisions about continuing current therapy, intensifying treatment, or switching to alternative approaches based on individual response patterns. - Ongoing Monitoring: Continue ctDNA measurements at regular intervals to track whether complete clearance is achieved, which correlates with the best long-term outcomes. What Are the Current Limitations? While the findings are promising, important barriers remain. The study was retrospective (looking backward at past patients) and included only 117 patients across multiple institutions, which is relatively small. Additionally, ctDNA testing requires tumor-informed platforms, meaning doctors must first analyze a patient's tumor tissue to identify specific DNA changes before developing a personalized blood test. This process takes time. Initial ctDNA results typically require several weeks to return, and subsequent checks usually take 1 to 2 weeks. "As of right now, you can't obtain ctDNA results in real time," Dr. Ma noted. Cost is another consideration, though the sources don't specify exact pricing. What's Next for This Research? Dr. Ma and colleagues are now expanding the study to include more institutions to validate these findings in larger patient populations. Future research will explore whether even earlier ctDNA measurements, potentially at 1 to 2 weeks after starting treatment, could provide even faster insights. Researchers are also investigating optimal ctDNA change thresholds. The current study found that patients with ctDNA increases greater than 20% from baseline had significantly worse outcomes, while those with decreases up to 20% had improved disease control and response rates, but more data is needed to refine these cutoff values. The broader context matters too. Immunotherapy has transformed melanoma from a disease with a median survival of just 6.5 months 15 years ago to one where more than half of patients now survive cancer-free for a decade or longer. However, immunotherapy still doesn't work for everyone and can cause severe side effects by overstimulating the immune system. Tools like ctDNA testing could help maximize benefits while minimizing unnecessary treatment exposure. For melanoma patients currently considering or undergoing immunotherapy, discussing ctDNA testing with your oncologist could provide valuable early insights into how your body is responding to treatment, potentially enabling faster adjustments if needed.
